Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-12-08 Purchase |
2021-12-10 8:33 pm |
Xilio Therapeutics Inc. | XLO | Bain Capital Life Sciences Investors LLC Bain Capital Life Sciences Fund II L.P. Bain Capital Life Sciences Investors II LLC BCLS II Investco LP BCLS II Investo (GP) LLC BCIP Life Sciences Associates LP 10% Owner |
42,469 | $9.6579 | $410,161 | 2,805,413 (Indirect) |
View |
| 2021-10-26 Purchase(A) |
2021-11-03 4:20 pm |
Xilio Therapeutics Inc. | XLO | SV7 Impact Medicine Fund LP SV7 (IMF) GP LLP 10% Owner |
625,000 | $16 | $10,000,000 | 3,227,264 (Indirect Direct) |
View |
| 2021-10-26 Purchase |
2021-10-28 7:15 pm |
Xilio Therapeutics Inc. | XLO | Flynn James E Deerfield Mgmt L.P. DEERFIELD PARTNERS L.P. DEERFIELD MANAGEMENT COMPANY L.P. (SERIES C) Deerfield Mgmt V L.P. Possible Member of 10% Group 10% Owner |
775,000 | $16 | $12,400,000 | 1,143,972 (Indirect) |
View |
| 2021-10-26 Purchase |
2021-10-26 5:30 pm |
Xilio Therapeutics Inc. | XLO | RiverVest Venture Fund IV L.P. 10% Owner |
250,000 | $16 | $4,000,000 | 1,441,444 (Indirect) |
View |
| 2021-10-26 Purchase |
2021-10-26 5:04 pm |
Xilio Therapeutics Inc. | XLO | Rock Springs Capital Management LP Rock Springs Capital LLC Rock Springs Capital Master Fund LP Four Pines Master Fund LP 10% Owner |
500,000 | $16 | $8,000,000 | 1,256,472 (Indirect) |
View |
| 2021-10-26 Purchase |
2021-10-26 5:02 pm |
Xilio Therapeutics Inc. | XLO | BAY CITY CAPITAL LLC 10% Owner |
312,500 | $16 | $5,000,000 | 1,129,490 (Indirect) |
View |
| 2021-10-26 Purchase |
2021-10-26 5:01 pm |
Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Opportunity Fund I L.P. 10% Owner |
187,500 | $16 | $3,000,000 | 735,942 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2021-12-22 Option Award |
2021-12-23 7:06 pm |
N/A 2031-12-21 |
Xilio Therapeutics Inc. | XLO | Russo Rene CEO AND PRESIDENT |
100,000 | $0 | 100,000 (Direct) |
View |
Ownership |
2021-11-05 6:26 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Bain Capital Life Sciences Investors LLC Bain Capital Life Sciences Fund II L.P. Bain Capital Life Sciences Investors II LLC BCLS II Investco LP BCLS II Investo (GP) LLC BCIP Life Sciences Associates LP 10% Owner |
0 | $0 | 2,762,944 (Indirect) |
View |
| 2021-10-26 Conversion(A) |
2021-11-03 4:20 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | SV7 Impact Medicine Fund LP SV7 (IMF) GP LLP 10% Owner |
26,022,654 | $0 | 3,227,264 (Direct) |
View |
| 2021-10-26 Conversion |
2021-10-28 7:15 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Flynn James E Deerfield Mgmt L.P. DEERFIELD PARTNERS L.P. DEERFIELD MANAGEMENT COMPANY L.P. (SERIES C) Deerfield Mgmt V L.P. Possible Member of 10% Group 10% Owner |
15,129,450 | $0 | 1,143,972 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-28 3:57 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | FIL Ltd See Remark 1 |
2,296,403 | $0 | 218,705 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-28 3:45 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | FMR LLC See Remark 1 |
19,754,248 | $0 | 30,780 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-28 12:55 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | SV7 Impact Medicine Fund LP SV7 (IMF) GP LLP 10% Owner |
26,022,654 | $0 | 2,602,264 (Direct) |
View |
| 2021-10-26 Conversion |
2021-10-26 8:31 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | TAKEDA PHARMACEUTICAL CO LTD Takeda Ventures Inc. 10% Owner |
2,950,242 | $0 | 1,475,121 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-26 5:30 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | RiverVest Venture Fund IV L.P. 10% Owner |
1,191,444 | $0 | 1,441,444 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-26 5:06 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Merck KGaA 10% Owner |
7,148,664 | $0 | 680,825 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-26 5:04 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Rock Springs Capital Management LP Rock Springs Capital LLC Rock Springs Capital Master Fund LP Four Pines Master Fund LP 10% Owner |
9,531,553 | $0 | 1,256,472 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-26 5:02 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | BAY CITY CAPITAL LLC 10% Owner |
8,578,397 | $0 | 1,129,490 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-26 5:01 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Opportunity Fund I L.P. 10% Owner |
26,728,062 | $0 | 735,942 (Indirect) |
View |
| 2021-10-26 Option Award |
2021-10-26 5:01 pm |
N/A 2030-07-22 |
Xilio Therapeutics Inc. | XLO | Clancy Paul J Director |
109,561 | $0 | 109,561 (Direct) |
View |
| 2021-10-26 Conversion |
2021-10-26 4:51 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Alexandria Venture Investments LLC 10% Owner |
1,747,449 | $0 | 166,423 (Direct) |
View |
| 2021-10-21 Option Award |
2021-10-25 5:18 pm |
N/A 2031-10-20 |
Xilio Therapeutics Inc. | XLO | Russo Rene CEO and President 10% Owner |
50,041 | $0 | 50,041 (Direct) |
View |
| 2021-10-21 Option Award |
2021-10-25 5:18 pm |
N/A 2031-10-20 |
Xilio Therapeutics Inc. | XLO | Ross Michael Jay Director |
26,400 | $0 | 26,400 (Direct) |
View |
| 2021-10-21 Option Award |
2021-10-25 5:17 pm |
N/A 2031-10-20 |
Xilio Therapeutics Inc. | XLO | Huber Martin H. Jr. President of R&D and CMO |
157,058 | $0 | 157,058 (Direct) |
View |
| 2021-10-21 Option Award |
2021-10-25 5:16 pm |
N/A 2031-10-20 |
Xilio Therapeutics Inc. | XLO | Giovine Salvatore Chief Financial Officer |
28,755 | $0 | 28,755 (Direct) |
View |
Ownership |
2021-10-22 8:16 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Williams John Charles 10% Owner |
0 | $0 | 100,080 (Direct) |
View |
Ownership |
2021-10-21 9:36 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Flynn James E Deerfield Mgmt L.P. DEERFIELD PARTNERS L.P. DEERFIELD MANAGEMENT COMPANY L.P. (SERIES C) Deerfield Mgmt V L.P. *Possible Member of 10% Group 10% Owner |
0 | $0 | 1,512,944 (Indirect) |
View |
Ownership |
2021-10-21 9:00 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | FIL Ltd See Remark 1 10% Owner |
0 | $0 | 218,705 (Indirect) |
View |
Ownership |
2021-10-21 8:59 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Alexandria Venture Investments LLC 10% Owner |
0 | $0 | 166,423 (Direct) |
View |
Ownership |
2021-10-21 8:53 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Estate of Ulrich Rodeck 10% Owner |
0 | $0 | 100,080 (Direct) |
View |
Ownership |
2021-10-21 8:52 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | CLACKSON TIMOTHY P 10% Owner |
0 | $0 | 111,751 (Direct) |
View |
Ownership |
2021-10-21 8:52 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | TOMLINSON SIMON M 10% Owner |
0 | $0 | 131,117 (Direct) |
View |
Ownership |
2021-10-21 8:51 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Rock Springs Capital Management LP Rock Springs Capital LLC Rock Springs Capital Master Fund LP Four Pines Master Fund LP 10% Owner |
0 | $0 | 907,766 (Indirect) |
View |
Ownership |
2021-10-21 8:50 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Merck KGaA 10% Owner |
0 | $0 | 680,825 (Indirect) |
View |
Ownership |
2021-10-21 8:49 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | BAY CITY CAPITAL LLC 10% Owner |
0 | $0 | 816,990 (Indirect) |
View |
Ownership |
2021-10-21 8:49 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | FMR LLC See Remark 1 10% Owner |
0 | $0 | 1,907,670 (Indirect) |
View |
Ownership |
2021-10-21 8:48 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI L.P. Atlas Venture Associates XI LLC Atlas Venture Opportunity Fund I L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC 10% Owner |
0 | $0 | 2,571,844 (Indirect) |
View |
Ownership |
2021-10-21 8:45 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Russo Rene CEO and President 10% Owner |
0 | $0 | 1,048,804 (Direct) |
View |
Ownership |
2021-10-21 8:45 pm |
N/A 2031-08-22 |
Xilio Therapeutics Inc. | XLO | Bonstein Sara Director |
0 | $0 | 53,213 (Direct) |
View |
Ownership |
2021-10-21 8:44 pm |
N/A 2031-03-28 |
Xilio Therapeutics Inc. | XLO | Giovine Salvatore Chief Financial Officer |
0 | $0 | 233,596 (Direct) |
View |
Ownership |
2021-10-21 8:44 pm |
N/A 2030-07-22 |
Xilio Therapeutics Inc. | XLO | Clancy Paul J Director |
0 | $0 | 58,134 (Direct) |
View |
Ownership |
2021-10-21 8:41 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | HUMPHREY RACHEL Director |
0 | $0 | 58,133 (Direct) |
View |
Ownership |
2021-10-21 8:40 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | RiverVest Venture Fund IV L.P. 10% Owner |
0 | $0 | 1,191,444 (Indirect) |
View |